Intended for US healthcare professionals only.

ZYDELIG® is a PI3Kδ inhibitor indicated for

the treatment of relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other comorbidities.

Limitations of use: ZYDELIG is not indicated and is not recommended for first-line treatment of any patient, including patients with CLL, small lymphocytic lymphoma (SLL), follicular lymphoma (FL), and other indolent non-Hodgkin lymphomas.

ZYDELIG is not indicated and is not recommended in combination with bendamustine and rituximab, or in combination with rituximab for the treatment of patients with FL, SLL, and other indolent non-Hodgkin lymphomas.

PI3Kδ=phosphatidylinositol 3-kinase.

ZYDELIG® AccessConnect®

Patient financial support

ZYDELIG AccessConnect is a central resource designed to help all patients navigate therapy and support offerings. Patients enrolled in ZYDELIG AccessConnect will be matched with a case specialist who can help answer financial questions related to ZYDELIG® and connect patients with the appropriate people and financial resources.

Download ZYDELIG AccessConnect support materials, including the patient enrollment form, at the bottom of this page. You can also enroll patients and get additional program details by visiting the ZYDELIG AccessConnect site.